For immediate release
New England Biolabs® announces supply agreement with Lumora.
Agreement further strengthens New England Biolabs' position as a key supplier to the molecular diagnostics sector.

5th March, 2014 (Ipswich, MA, USA) New England Biolabs, Inc. (NEB®), a world leader in the production and supply of recombinant enzymes and related reagents for the life science industry, has strengthened its position as a key supplier to the fast-growing molecular diagnostics market by signing an agreement to manufacture and supply critical reagents to Lumora, a provider of state-of-the-art molecular in vitro diagnostic products.

Under the terms of the agreement, NEB will manufacture and supply its proprietary Bst 2.0 DNA Polymerase, a robust enzyme for isothermal amplification and a key component of Lumora's Bioluminescent Assay in Real Time (BART) technology. NEB will also manufacture and supply a range of supporting reagents for use in the development and commercialization of Lumora's molecular diagnostics assay products.

Lumora's Commercial Director Hayden Jeffreys commented, "NEB is one of the leading suppliers of molecular biology enzymes and associated reagents for life science research. This agreement will allow us to access NEB's expertise and reagents, ensuring we are able to provide our customers and partners with the most effective diagnostics."

"We are pleased to formalize our relationship with Lumora by applying our technical and commercial expertise, so that Lumora's technology continues to be a success in the molecular diagnostics market." said Dr. Kiran Gulati, Associate Director, Business Development for Europe at NEB. "NEB has built a strong reputation with a large number of customers across the life sciences sector, and is serving a growing share of molecular diagnostics manufacturers' needs for key reagents. By working with innovative companies with strong technologies, such as Lumora, we can help ensure that these technologies achieve commercial success."

 

For more information about Bst DNA Polymerase, or NEB's custom capabilities for molecular diagnostics, contact This email address is being protected from spambots. You need JavaScript enabled to view it.

 

For further information please contact:

 

Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Deana D. Martin, Ph.D.
Marketing Communications Manager
New England Biolabs
240 County Road
Ipswich, MA, USA 01938
Tel: 978-380-7464
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.
Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.
www.lumora.co.uk

 

About New England Biolabs

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.
NEW ENGLAND BIOLABS® AND NEB® are registered trademarks of New England Biolabs, Inc.
www.neb.com

UNITAID Report Highlights Lumora’s Technology for Viral Load Monitoring for HIV

Cambridgeshire, UK, 17 February 2014

Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has been named in the UNITAID HIV/AIDS Diagnostic Technology Report that highlights innovative new diagnostic technologies for viral load monitoring at or near the point of patient care.
Lumora’s HIV Viral Load BART (Bioluminescent Assay in Real Time) is due to be ready to transfer to a commercial partner during 2014 and aims to be one of the most inexpensive technologies on the market for assessing the viral load of HIV patients. The BART assay is expected to cost around $10 per test and the instrument will cost about $1,000. This compares favourably to laboratory-based viral load platforms on the market, for which the instrumentation alone can cost up to $100,000, and per test costs range from $10 to $40 or more.
In addition, Lumora’s viral load BART is rapid, with a turnaround time of about 60 minutes. Laboratory-based assays can take more than 3 hours to complete. The company believes that the viral load assay for use on the BART platform will be one of the fastest and easiest to use.
The company believes it has demonstrated that BART is a proven platform for low resource settings through the adoption in more than 30 countries of its food pathogen test and platform that includes Lumora’s robust and easy-to-use technology.
Lawrence Tisi, CEO of Lumora, said: “The ability to monitor HIV patients is crucial to ensuring they receive the best treatment. While this is relatively easy in the western world, for patients in the developing world, it is a much greater issue. Many of the machines are expensive to buy, limiting their use, and the cost and time involved in doing a single test can make it prohibitive. This report neatly summarises the range of assays available, showing just how competitive Lumora’s BART assay will be.”
Hayden Jeffreys, Commercial Director at Lumora, added: “With our HIV Viral Load BART assay ready to be commercialised by a partner this report is extremely timely. It shows the advantages of Lumora’s BART technology, namely in terms of price, but also its speed of use. At the same time, the instrument is handheld and easily portable, meaning it can be used in a wide range of environments.
Based in Geneva and hosted by the World Health Organization, UNITAID uses innovative financing to increase funding for greater access to treatments and diagnostics for HIV/AIDS, malaria and tuberculosis in low-income countries. The full report can be found at: http://www.unitaid.eu/images/marketdynamics/publications/UNITAID-HIV_Diagnostic_Landscape-3rd_edition.pdf
The UNITAID semi-annual update can also be found at: http://www.unitaid.eu/images/UNITAID_2013_Semi-annual_Update_HIV_Diagnostics_Technology_Landscape.pdf
-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications

Hayden Jeffreys Appointed to Board of Lumora

 

Cambridgeshire, UK, 22 January 2014 ...

Lumora, a successful provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, is pleased to announce that it has appointed Hayden Jeffreys to its Board of Directors.

Hayden joined Lumora from Lab21 in January 2013 as Commercial Director, and since joining Lumora, Hayden has been instrumental in securing a number of deals with global companies and organisations. Hayden has also been responsible for marketing Lumora’s latest invention known as “Heat Elution”, Lumora’s patented sample preparation technology, which significantly reduces the time and complexity involving in testing samples. Prior to Lab21, Hayden held positions at Invitron, Gen-Probe and Molecular Light Technology.

Laurence Tisi, CEO of Lumora said: “Hayden has been a fantastic addition to the team. His commercial knowledge coupled with the scientific excellence of the team has enabled us to close a number of key commercial deals, which have significantly strengthened the company. Hayden’s appointment to the board is richly deserved and his ability, dedication and hard work will be instrumental to Lumora’s continued success.”

 

-ends-

 

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.
www.lumora.co.uk

Under embargo for
17:00 EST/22:00 GMT 8 January 2014

 

New technology applied to rapidly detect C. difficile in a clinical setting 
PLOS research shows new technique is more than twice as fast as current gold standard

 

Cambridgeshire, UK, 8 January 2014 ...

Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has developed a new test for C. difficile which is more than twice as fast as current clinical techniques.

 

The research, which is published in PLOS ONE, describes how C. difficile was detected from a stool sample using a recently developed rapid, novel and low complexity extraction process called Heat Elution (HE). Using heat elution, the sample preparation process took around ten minutes compared to nearly an hour for traditional techniques.

 

The test was evaluated in a pilot study on clinical fecal samples and was developed using HE in conjunction with an Isothermal Amplification and Lumora’s BART technology

The HE- -BART method showed 95.5% sensitivity and 100% specificity against a gold standard reference method using cytotoxigenic culture and also a silica-based robotic extraction followed by PCR to control for storage. From sample to result, the HE- -BART method typically took 50 minutes, whereas the PCR method took over 2.5 hours.

 

The research also compared this new approach with another commercially available method, Illumigene (Meridian Bioscience, OH), and found the combined HE- -BART method had 87.2% sensitivity and 100% specificity, compared to 76.6% 14 and 100%, respectively, for Illumigene.

Laurence Tisi, CEO of Lumora, said: “This research shows the strength of our technology and work flow. By combining proven technologies such as BART with our new sample preparation technology, we have developed a highly effective and rapid test for a common bacteria which can be responsible for significant ill health.”

 

Hayden Jeffreys, Commercial Director of Lumora, said: “The commercial opportunities for this test are significant. Using this test will enable healthcare professionals to quickly and accurately test suspected cases and take appropriate action to limit the further spread. Furthermore, by showing its effectiveness against one of the most commonly used diagnostics we believe this should lead to significant interest.”

 

This deal follows a series of milestones for Lumora this year, including a deal with Promega to supply reagents, a deal with Biogal to provide veterinary diagnostics, a partnership with FIND (Foundation for Innovative New Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.

 

-ends-

 

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Notes to Editors:
The full PLOS One paper can be found at http://dx.plos.org/10.1371/journal.pone.0083808

 

About Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

www.lumora.co.uk

Patent Published for Lumora’s Novel Sample Preparation Technology

Cambridgeshire, UK, 31 October 2013 ...

 

Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has received a patent for its Heat Elution Sample Preparation, technology which has the potential to help commercial laboratories simplify the process and save valuable time and money in sample preparation.

The new sample preparation technique, Heat Elution, uses the power produced by heat lysis in a sealed vessel to drive elution through inhibitor removing materials, a by-product of sample preparation. By adding the sample to inhibitor removing materials in a sealed environment, the pressure caused by the heat lysis is able to cause elution, the process of separating the materials for testing. This means there is no need for complex and costly robotics or pumps, yet nucleic acids are produced in a suitably pure form ready for PCR or isothermal amplification. The process also combines purification with the heat lysis step, removing several steps from the sample preparation.

In addition to reducing the time needed for sample preparation, studies have indicated that this process may well improve sensitivity compared with traditional techniques.

The international patent number is International Patent Application No. PCT/GB2013/050846.

Laurence Tisi, CEO of Lumora said: “Sample preparation is a significant part of any scientists work when testing samples. Current techniques can be complex, labour intensive and expensive. We believe that this technique along with other sample prep technologies we are developing will help save a significant amount of time, effort and cost. Our aim is not only to make sample preparation easier and allow it to be done in non-specialised facilities, meaning it could be easily deployed in the developing world for tackling diseases such as HIV.”

Hayden Jeffreys, Commercial Director of Lumora, added: “Anything that reduces the time spent in sample preparation could provide significant cost savings to commercial labs by reducing the amount of time required for testing. Not only does this process reduce the time required for sample preparation, data also shows that it has an increased sensitivity when compared with traditional sample preparation.”

The patent news is another milestones for Lumora this year, which also includes a deal with Promega to provide re-agents, a deal with Biogal to provide veterinary diagnostics and a partnership with FIND (Foundation for Innovative New Diagnostics) to develop a novel malaria diagnostic.

-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.
www.lumora.co.uk

Lumora Signs Supply Agreement with Promega for Ultra-Glo Luciferase, to be used in Lumora's BART Molecular Diagnostics Technology

Cambridgeshire, UK , 22 July 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, and Promega, a leader in providing innovative solutions and technical support to the life sciences industry, have signed a supply agreement for the use of Promega's Ultra-Glo™ luciferase in Lumora's BART (Bioluminescent Assay in Real-Time) molecular diagnostics technology.

Lumora's BART technology is a novel reporter system, designed to be used with isothermal nucleic acid amplification technologies - primarily as a tool in molecular diagnostics. This is the first commercial molecular diagnostic application for Promega's Ultra-Glo luciferase, highlighting the potential of the bioluminescent enzyme when combined with cutting edge technologies such as BART.

Hayden Jeffreys, Commercial Director at Lumora, said: "This is a significant deal for both parties as it showcases the application of Ultra-Glo, a highly regarded reagent, in the fast growing area of molecular diagnostics. Promega has established itself as one of the best suppliers of reagents in the world, and by leveraging their global presence, combined with the potential applications of BART and Ultra-Glo, we believe this deal could be the start of a significant partnership."

Laurence Tisi, CEO of Lumora, said: "The BART technology represents the first of a new generation of bioluminescent assays which take advantage of the ability of Ultra-Glo to operate at temperatures in excess of 60˚C. BART bridges bioluminescent and molecular technologies in a unique way offering a breakthrough in the simplicity and robustness of molecular assays."

Matthew Cook, Head of Commercial Sales, Promega, added: "We are very pleased to collaborate with Lumora. The company has some excellent technologies in the molecular diagnostics space, which combined with Ultra-Glo has the potential to open new markets."

The BART technology causes a sample to emit light when a diagnostic test result is positive, making the technology extraordinarily simple to implement and eliminating the need for highly sensitive light detection apparatus. The simplicity of BART enables easy-to-use, affordable, robust hardware to be used. This is a major break-through as molecular diagnostics is typically associated with complex and expensive hardware.

This deal follows a series of milestones for Lumora this year, including a deal with Biogal to provide veterinary diagnostics, a partnership with FIND (Foundation for Innovative New Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.

-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very
active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

www.lumora.co.uk

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com

Latest scientific studies highlight the effectiveness of LAMP based diagnostics

 

 

New scientific studies have shown that LAMP (Loop Meditated Isothermal Amplification) based technologies could have a significant role in dealing with endemic diseases such as malaria.

The peer reviewed research which appeared in the Journal of Infectious Diseases shows how LAMP can be used as a tool or the quick and easy diagnosis of malaria in both modernized laboratories and in the field in areas of the world where the disease is endemic.

The studies highlighted the potential of Lumora’s work in this area, and its recent deal with FIND (Foundation for Innovative Novel Diagnostics) which will see the development of a new malaria test using BART (Bioluminescent Assay in Real Time), a technology based on LAMP .

 "Using this test requires only a room with very basic laboratory facilities, i.e. electricity," Iveth Gonzalez, a scientific officer and project manager of LAMP projects for malaria and Chagas disease at FIND, and an author on the studies, told PCR Insider. "This test can be used in any microscopy-level clinic in resource-poor nations and doesn’t need standard infrastructure for PCR."

"The current LAMP kit has been developed for case management, and small groups of samples can be tested simultaneously," Gonzalez said. "FIND is working with Lumora [to develop] the next generation of the assay which is a high-throughput format that will allow testing of bigger groups of samples. The application of this assay will mainly be for population screening in elimination campaigns."

In April, Lumora agreed a partnership with FIND to develop a rapid, high-throughput malaria diagnostic assay for screening patients in the developing world.

Lumora agrees licence and development program for Veterinary applications with Biogal Galed Labs

Cambridge, UK, Tuesday 28th May 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has entered into a license and development agreement with Biogal Galed Labs ACS Ltd, a provider of veterinary diagnostics, to develop a series of veterinary tests.

The partnership will allow Biogal Galed Labs ACS Ltd to access Lumora’s enabling technologies such as BART (Bioluminescent Assay in Real Time), as well as  the company’s proven know-how in test development, reader technologies and manufacturing.

The partnership will involve a significant pipeline of test development, starting with Leptosporis, a zoonotic bacterial infection transmitted through the urine of animals. Financial details were not disclosed.

Hayden Jeffreys, Commercial Director at Lumora, said: “This partnership further illustrates the broad utility of Lumora’s technology. The simplicity, robustness and ease of use, make BART and our other technologies very applicable to the non-traditional molecular environment, whether this in the industrial applications or in the clinical market.”

Laurence Tisi, CEO of Lumora, added:  “This deal with Biogal will showcase the benefits of working with Lumora’s expert team and its focus on delivering partner’s products to market in the shortest time possible.  With the Leptosporosis test progressing through development, we have already initiated work on a series of additional assays in the planned development pipeline.”

A spokesperson from Biogal commented, “We are excited to be able to partner with Lumora. They have an excellent track record of producing high quality assays for their partners, across a wide range of applications. Through this partnership we aim to provide our customers with advanced diagnostics which can be provided in all sizes of veterinary labs.”

The deal with Biogal follows a series of milestones for Lumora this year, including a partnership with FIND (Foundation for Innovative Novel Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.

-ends-

For further information please contact:

Tony Stephenson, Director

Exitus Communications

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Notes to Editors: 

Lumora

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.

 

www.lumora.co.uk

Biogal Galed Labs ACS Ltd

Biogal, is a private company owned by Kibbutz Galed and is headquartered in northern Israel. It was established in 1986.Biogal – Galed Laboratories is dedicated to the development, manufacturing and marketing of excellent diagnostic tools for companion animals, poultry, farm animals and laboratory rodents. Customer oriented services lead us forward in our search for excellence, efficiency and innovation.

http://biogal.co.il/

Lumora to partner with FIND to develop new, high-throughput Malaria molecular diagnostic test for use in the developing world

Cambridge, UK, 15th April 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has partnered with The Foundation for Innovative New Diagnostics (FIND) to develop a rapid, high-throughput malaria diagnostic assay for screening patients in the developing world.

The partnership will allow FIND to access Lumora’s technologies such as BART (Bioluminescent Assay in Real Time) and the company’s expertise to develop a novel test that will allow rapid screening on a large scale.

Strategies for the elimination of malaria are held back by lack of screening technologies for use in the field that can detect hidden or low parasitemia malaria infections, and thus stamp out the final cases. Such screening would also then help to keep these populations malaria free. The first field test with sufficient sensitivity to detect as few as one malaria parasite in a finger-prick blood sample has recently been developed and released by FIND and Eiken Chemical (Japan). The partnership with Lumora, funded by the BMBF of Germany, will enable the malaria LAMP test to be scaled into a high-throughput screening test specifically designed for malaria elimination programmes.
 
Laurence Tisi, CEO of Lumora, said: “This partnership illustrates that by combining the versatility and strength of Lumora’s technologies, with the expertise of the team, we can develop a diagnostic which can be deployed in both a traditional and non traditional clinical setting . We are extremely pleased that FIND have recognised that Lumora’s approach of simplifying molecular diagnostics, through the application of its proprietary technologies such as BART, will bring significant benefit not only to the clinical market but more importantly to those who work in malaria control and elimination.”

“This partnership opens the way to fill one of the major gaps in the malaria elimination agenda”, said David Bell, head of the malaria and acute fever programme at FIND. “LAMP technology has already proven to be the most robust field technology for high-sensitivity diagnosis, currently entering programmes for elimination of both malaria and sleeping sickness and under development for a number of other diseases. Adding this high-throughput platform opens the way for a range of new diagnostic screening applications that could prove pivotal in managing several diseases of both human and animal health.”
 
Hayden Jeffreys, Commercial Director at Lumora, added: “We see the partnership with FIND as an important stepping stone to providing a greater menu of products utilising our technology in clinical setting s to complement our HIV portfolio, which includes Lumora’s viral load test. We look forward to extending this partnership in order to commercialise this product and the many others in our pipeline.”

-ends-

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very
active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Cambridge Enterprise, (University of Cambridge) Tate Lyle Ventures LP, and Catapult Venture Managers Ltd.

www.lumora.co.uk

FIND
The Foundation for Innovative New Diagnostics is dedicated to developing affordable, easy-to-use and cutting edge diagnostic tests that save lives in the poorest areas of the world. From proof of principle to putting new tests into practice, the organization works with multiple and diverse groups, from academia, industry, donors, partners in the field, Ministries of Health and the World Health Organization. With new diagnostics for malaria, TB and sleeping sickness already in use, FIND is also working on other neglected diseases, such as Chagas disease and leishmaniasis and other causes of acute fever. Launched in 2003, the not-for-profit Foundation is ISO certified and financed by both the private and public sectors, including the Bill & Melinda Gates Foundation, Government of the Netherlands, the European Union, UNITAID, UK Department for International Development, National Institutes of Health (USA), UBS Optimus Foundation and others.

http://www.finddiagnostics.org/

Lumora completes follow on fundraising

Company raises £700,000 to accelerate commercial development

 

Cambridge, UK, 18th March 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has completed a follow on fund raising as it looks to progress its molecular diagnostics applications in the US and Europe.

Lumora has raised £700,000 from current investors including Tate & Lyle Ventures, Catapult Ventures Managers and Cambridge University. The funding will be used to further commercialise Lumora’s molecular diagnostic technologies and applications including the BART system (Bioluminescent Assay in Real Time), along with Lumora’s other proprietary technologies.

Laurence Tisi, CEO of Lumora said: “This funding is excellent news and demonstrates the support that the business has from its investors and shareholders, particularly in this challenging economic climate. During this quarter we have made significant progress with a number of commercial deals and the funding will allow us to further develop new products, take advantage of new opportunities, and accelerate existing commercial agreements.”

David Atkinson, Managing Partner, Tate & Lyle Ventures stated: “We are delighted to continue to support Lumora given the technical milestones it has achieved and look forward to further commercial success in the coming months.”

The fundraising builds on a busy start to 2013 for Lumora, with the appointments of Jim Reid as Chairman and Hayden Jeffreys as Commercial Director. At the same time, the company is developing a number of significant commercial deals in the clinical, industrial and veterinary sectors.

Hayden Jeffreys, Commercial Director at Lumora, added: “We are pleased with the strong commercial progress we are making and expect a number of important announcements over the coming months. As well as announcing the first of our clinical development agreements from our pipeline, we also expect to announce our next industrial licensing deal in the veterinary field.”

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very
active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Cambridge Enterprise (University of Cambridge), Tate & Lyle Ventures LP, and Catapult Venture Managers Ltd.

www.lumora.co.uk

Lumora appoints Industry Veteran, Jim Reid, as Chairman as Company gears up for major commercial push

 

Cambridge, UK, Monday 11 February 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, has appointed Jim Reid as Chairman.

 

Jim brings a wealth of experience to the board at Lumora, having spent over 35 years in the bioscience and diagnostic industries in a number of positions across Europe, with Organon, Bioscot, Roche, Chiron and Trinity Biotech. He also holds a number of non-executive director positions including Sistemic Ltd., Ocutec Ltd., and BioFilm Ltd. He has been involved in the molecular diagnostic industry since the late 1980s and was responsible for the first introduction of molecular diagnostic tests to the UK in 1991 while at Roche. Jim has also successfully developed a number of molecular diagnostic companies and has successful exits from some of these including the sale of Qnostics to BBI plc (now Alere).

 

Laurence Tisi, CEO of Lumora said: “Jim’s appointment comes at an important time for the business during a phase of significant growth and opportunity. Having significantly strengthened the management team, and with Jim’s appointment as Chairman, Lumora is now well placed to fulfil its ambitions and become a significant force in the global molecular diagnostics market.”

 

Jim Reid added: “Lumora has developed some excellent technologies which could be transformational for the molecular diagnostic industry. The molecular diagnostic sector is the fastest growing sector of the diagnostic market and Lumora is well placed to offer partners a significant step-change in crucial areas which have proved difficult or impossible to address with existing technologies. The potential to move molecular testing close to the patient, without the need for sophisticated laboratories or expensive equipment, means that the industry can deliver the promise of true near patient testing.”

 

For further information please contact:

Tony Stephenson, PR Consultant

Tel: +44 (0)7899 796655

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Download PDF here

 

Notes to Editors:

Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

 

Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Cambridge Enterprise, (University of Cambridge) Tate Lyle Ventures LP, and Catapult Venture Managers Ltd.

News